Skip to content

Login
Menu
- I am...
- Member Organisations
  - - - Membership Organisation
        
        With over 90 member organisations in 55 countries, Lymphoma Coalition strives to be a central hub for resources and information sharing among its member organisations.
- Healthcare Professional
  - - - Healthcare Professional
        
        Important information for physicians, healthcare professionals and researchers including treatment reports, patient resources, Global Patient study reports and other LC reasearch papers.
- Affected by Lymphoma
  - - - Affected by Lymphoma
        
        Lymphoma affects us all in different ways. Learn about lymphoma, browse our library of resources and connect with one of our member organisations near you.
- Researcher or Advocate
  - - - Past Research & Abstracts
      - Find a Local Organisation
    - - Researcher or Advocate
        
        News related to advocacy and policy for patient advocates and those interested in these areas, including information about health literacy, health technology assessment and regulatory processes, healthcare and health systems, data and research across the lymphoma landscape.
- About Us
- Learn about Lymphoma
- Research and Reports
- Find a Membership Organisation
- Lymphoma Coalition Updates
- World Lymphoma Awareness Day
- Donate

Home / Resource Library / Venetoclax Plus Obinutuzumab Prolongs PFS, Not OS, in Chronic Lymphocytic Leukemia

Venetoclax Plus Obinutuzumab Prolongs PFS, Not OS, in Chronic Lymphocytic Leukemia

EHA 2021

LYMPHOMA COALITION
445 – 1460 The Queensway
Etobicoke, ON M8Z 1S4
Canada
Not-For-Profit Business Number: 803211465

Privacy Policy | Contact Us

Not-For-Profit Business Number: 803211465.
Copyright © 2026 Lymphoma Coalition. All rights reserved.

The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or require more detailed information on the best course of treatment for you.